Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Social Connectedness Factors that Facilitate Use of Healthcare Services: Comparison of Transgender and Gender Nonconforming and Cisgender Adolescents.

Taliaferro LA, Harder BM, Lampe NM, Carter SK, Rider GN, Eisenberg ME.

J Pediatr. 2019 May 9. pii: S0022-3476(19)30444-5. doi: 10.1016/j.jpeds.2019.04.024. [Epub ahead of print]

PMID:
31079853
2.

Healthworlds, Cultural Health Toolkits, and Choice: How Acculturation Affects Patients' Views of Prescription Drugs and Prescription Drug Advertising.

Adams C, Harder BM, Chatterjee A, Hayes Mathias L.

Qual Health Res. 2019 Feb 9:1049732319827282. doi: 10.1177/1049732319827282. [Epub ahead of print]

PMID:
30741092
3.

Nonclinical safety assessment of a human interleukin-22FC IG fusion protein demonstrates in vitro to in vivo and cross-species translatability.

Lee DW, Zhong S, Pai R, Rae J, Sukumaran S, Stefanich EG, Lutman J, Doudement E, Wang X, Harder B, Lekkerkerker A, Herman A, Ouyang W, Danilenko DM.

Pharmacol Res Perspect. 2018 Nov 15;6(6):e00434. doi: 10.1002/prp2.434. eCollection 2018 Dec.

4.

Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma.

Harder BG, Blomquist MR, Wang J, Kim AJ, Woodworth GF, Winkles JA, Loftus JC, Tran NL.

Front Oncol. 2018 Oct 23;8:462. doi: 10.3389/fonc.2018.00462. eCollection 2018. Review.

5.

The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.

Hersh DS, Harder BG, Roos A, Peng S, Heath JE, Legesse T, Kim AJ, Woodworth GF, Tran NL, Winkles JA.

Neuro Oncol. 2018 Sep 3;20(10):1321-1330. doi: 10.1093/neuonc/noy063.

PMID:
29897522
6.

Beyond unequal access: Acculturation, race, and resistance to pharmaceuticalization in the United States.

Adams C, Chatterjee A, Harder BM, Mathias LH.

SSM Popul Health. 2018 Apr 12;4:350-357. doi: 10.1016/j.ssmph.2018.04.003. eCollection 2018 Apr.

7.

Bat detective-Deep learning tools for bat acoustic signal detection.

Mac Aodha O, Gibb R, Barlow KE, Browning E, Firman M, Freeman R, Harder B, Kinsey L, Mead GR, Newson SE, Pandourski I, Parsons S, Russ J, Szodoray-Paradi A, Szodoray-Paradi F, Tilova E, Girolami M, Brostow G, Jones KE.

PLoS Comput Biol. 2018 Mar 8;14(3):e1005995. doi: 10.1371/journal.pcbi.1005995. eCollection 2018 Mar.

8.

Low-level arsenic causes proteotoxic stress and not oxidative stress.

Dodson M, de la Vega MR, Harder B, Castro-Portuguez R, Rodrigues SD, Wong PK, Chapman E, Zhang DD.

Toxicol Appl Pharmacol. 2018 Feb 15;341:106-113. doi: 10.1016/j.taap.2018.01.014. Epub 2018 Feb 3.

9.

Temperature-dependent dynamic control of the TCA cycle increases volumetric productivity of itaconic acid production by Escherichia coli.

Harder BJ, Bettenbrock K, Klamt S.

Biotechnol Bioeng. 2018 Jan;115(1):156-164. doi: 10.1002/bit.26446. Epub 2017 Oct 6.

10.

Arsenic Compromises Both p97 and Proteasome Functions.

Tillotson J, Zerio CJ, Harder B, Ambrose AJ, Jung KS, Kang M, Zhang DD, Chapman E.

Chem Res Toxicol. 2017 Jul 17;30(7):1508-1514. doi: 10.1021/acs.chemrestox.7b00158. Epub 2017 Jul 7.

11.

Brusatol overcomes chemoresistance through inhibition of protein translation.

Harder B, Tian W, La Clair JJ, Tan AC, Ooi A, Chapman E, Zhang DD.

Mol Carcinog. 2017 May;56(5):1493-1500. doi: 10.1002/mc.22609. Epub 2017 Feb 8.

12.

Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients.

Schuster AK, Harder BC, Schlichtenbrede FC, Jarczok MN, Tesarz J.

Cochrane Database Syst Rev. 2016 Nov 14;11:CD011503. Review.

13.

Model-based metabolic engineering enables high yield itaconic acid production by Escherichia coli.

Harder BJ, Bettenbrock K, Klamt S.

Metab Eng. 2016 Nov;38:29-37. doi: 10.1016/j.ymben.2016.05.008. Epub 2016 Jun 4.

PMID:
27269589
14.

Best practice recommendations for the transfer of cell-based assays for the measurement of neutralizing anti-drug antibodies.

Belouski SS, Born D, Jacques S, Harder B, Reynhardt K, Kaliyaperumal A, Gupta S.

Bioanalysis. 2016 Sep;8(17):1845-57. doi: 10.4155/bio-2016-4998. Epub 2016 Aug 15.

PMID:
27523191
15.

Reduced Nrf2 expression mediates the decline in neural stem cell function during a critical middle-age period.

Corenblum MJ, Ray S, Remley QW, Long M, Harder B, Zhang DD, Barnes CA, Madhavan L.

Aging Cell. 2016 Aug;15(4):725-36. doi: 10.1111/acel.12482. Epub 2016 Apr 20.

16.

Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention.

Harder B, Jiang T, Wu T, Tao S, Rojo de la Vega M, Tian W, Chapman E, Zhang DD.

Biochem Soc Trans. 2015 Aug;43(4):680-6. doi: 10.1042/BST20150020. Epub 2015 Aug 3. Review.

17.

p62 links autophagy and Nrf2 signaling.

Jiang T, Harder B, Rojo de la Vega M, Wong PK, Chapman E, Zhang DD.

Free Radic Biol Med. 2015 Nov;88(Pt B):199-204. doi: 10.1016/j.freeradbiomed.2015.06.014. Epub 2015 Jun 24. Review.

18.

[Living liver donor: indications and technical aspects].

Nadalin S, Capobianco I, Königsrainer I, Harder B, Königsrainer A.

Chirurg. 2015 Jun;86(6):609-21; quiz 622. doi: 10.1007/s00104-015-0017-9. Review. German.

PMID:
26016710
19.

Hospital quality reporting by US News & World Report: why, how, and what's ahead.

Harder B, Comarow A.

JAMA. 2015 May 19;313(19):1903-4. doi: 10.1001/jama.2015.4566. No abstract available.

PMID:
25988456
20.

Reply: To PMID 25217855.

Schuster AK, Steinmetz P, Forster TM, Schlichtenbrede FC, Harder BC, Jonas JB.

Am J Ophthalmol. 2015 May;159(5):995-6. doi: 10.1016/j.ajo.2015.01.035. No abstract available.

PMID:
25867594
21.

Reply: To PMID 25217855.

Schuster AK, Steinmetz P, Forster TM, Schlichtenbrede FC, Harder BC, Jonas JB.

Am J Ophthalmol. 2015 Jan;159(1):208. doi: 10.1016/j.ajo.2014.10.002. No abstract available.

PMID:
25488647
22.

Choroidal Thickness in Open-angle Glaucoma.

Jonas JB, Steinmetz P, Forster TM, Schlichtenbrede FC, Harder BC.

J Glaucoma. 2015 Oct-Nov;24(8):619-23. doi: 10.1097/IJG.0000000000000063.

PMID:
25415643
23.

Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene.

Canet MJ, Merrell MD, Harder BG, Maher JM, Wu T, Lickteig AJ, Jackson JP, Zhang DD, Yamamoto M, Cherrington NJ.

Drug Metab Dispos. 2015 Jan;43(1):93-9. doi: 10.1124/dmd.114.060103. Epub 2014 Oct 27.

24.

Choroidal thickness in nonarteritic anterior ischemic optic neuropathy.

Schuster AK, Steinmetz P, Forster TM, Schlichtenbrede FC, Harder BC, Jonas JB.

Am J Ophthalmol. 2014 Dec;158(6):1342-1347.e1. doi: 10.1016/j.ajo.2014.09.008. Epub 2014 Sep 8.

PMID:
25217855
25.

Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?

Wu T, Harder BG, Wong PK, Lang JE, Zhang DD.

Mol Carcinog. 2015 Nov;54(11):1494-502. doi: 10.1002/mc.22202. Epub 2014 Aug 23.

26.

[Entropion: objective and subjective evaluation of two different surgical procedures].

Harder BC, von Balz S, Schlichtenbrede F, Jonas JB, Schuster AK.

Klin Monbl Augenheilkd. 2014 Jul;231(7):729-34. doi: 10.1055/s-0034-1368373. Epub 2014 Apr 30. German.

PMID:
24788605
27.

Hospital rankings in 'U.S. News'.

Harder B.

Health Aff (Millwood). 2014 Apr;33(4):722. doi: 10.1377/hlthaff.2014.0140. No abstract available.

PMID:
24711336
28.

Plant extracts of the family Lauraceae: a potential resource for chemopreventive agents that activate the nuclear factor-erythroid 2-related factor 2/antioxidant response element pathway.

Shen T, Chen XM, Harder B, Long M, Wang XN, Lou HX, Wondrak GT, Ren DM, Zhang DD.

Planta Med. 2014 Mar;80(5):426-34. doi: 10.1055/s-0034-1368197. Epub 2014 Feb 28. Erratum in: Planta Med. 2014 Nov;80(7):1664.

29.

Pharmacological evidence for an abstinence-induced switch in 5-HT1B receptor modulation of cocaine self-administration and cocaine-seeking behavior.

Pentkowski NS, Harder BG, Brunwasser SJ, Bastle RM, Peartree NA, Yanamandra K, Adams MD, Der-Ghazarian T, Neisewander JL.

ACS Chem Neurosci. 2014 Mar 19;5(3):168-76. doi: 10.1021/cn400155t. Epub 2014 Jan 15.

30.

Target refraction for best uncorrected distance and near vision in cataract surgery.

Schuster AK, Schlichtenbrede FC, Harder BC, Beutelspacher SC, Jonas JB.

Eur J Ophthalmol. 2014 Jul-Aug;24(4):509-15. doi: 10.5301/ejo.5000414. Epub 2013 Dec 16.

PMID:
24366766
31.

Systems metabolic engineering of Corynebacterium glutamicum for production of the chemical chaperone ectoine.

Becker J, Schäfer R, Kohlstedt M, Harder BJ, Borchert NS, Stöveken N, Bremer E, Wittmann C.

Microb Cell Fact. 2013 Nov 15;12:110. doi: 10.1186/1475-2859-12-110.

32.

Choroidal thickness in age-related macular degeneration.

Jonas JB, Forster TM, Steinmetz P, Schlichtenbrede FC, Harder BC.

Retina. 2014 Jun;34(6):1149-55. doi: 10.1097/IAE.0000000000000035.

PMID:
24220257
33.

Intravitreal low-dosage bevacizumab for retinopathy of prematurity.

Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC.

Acta Ophthalmol. 2014 Sep;92(6):577-81. doi: 10.1111/aos.12266. Epub 2013 Sep 11.

34.

Implanted islets in the anterior chamber of the eye are prone to autoimmune attack in a mouse model of diabetes.

Mojibian M, Harder B, Hurlburt A, Bruin JE, Asadi A, Kieffer TJ.

Diabetologia. 2013 Oct;56(10):2213-21. doi: 10.1007/s00125-013-3004-z. Epub 2013 Aug 11.

PMID:
23933952
35.

Are MOOCs the future of medical education?

Harder B.

BMJ. 2013 Apr 26;346:f2666. doi: 10.1136/bmj.f2666. No abstract available.

PMID:
23624666
36.

Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.

Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB.

Am J Ophthalmol. 2013 Jun;155(6):1119-1124.e1. doi: 10.1016/j.ajo.2013.01.014. Epub 2013 Mar 12.

PMID:
23490192
37.

Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.

Pan WJ, Hsu H, Rees WA, Lear SP, Lee F, Foltz IN, Rathanaswami P, Manchulenko K, Chan BM, Zhang M, Xia XZ, Patel SK, Prince PJ, Doherty DR, Sheckler CM, Reynhardt KO, Krill CD, Harder BJ, Wisler JA, Brandvig JL, Lynch JL, Anderson AA, Wienkers LC, Borie DC.

Br J Pharmacol. 2013 May;169(1):51-68. doi: 10.1111/bph.12134.

38.

Instructor comfort level in high-fidelity simulation.

Harder BN, Ross CJ, Paul P.

Nurse Educ Today. 2013 Oct;33(10):1242-5. doi: 10.1016/j.nedt.2012.09.003. Epub 2012 Sep 29.

PMID:
23025906
39.

Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.

Harder BC, von Baltz S, Schlichtenbrede FC, Jonas JB.

Arch Ophthalmol. 2012 Jun;130(6):800-1. doi: 10.1001/archophthalmol.2012.1. No abstract available.

PMID:
22801850
40.

[Causes, diagnostics and therapy for paediatric ptosis].

Ungerechts R, Grenzebach U, Harder B, Emmerich KH.

Klin Monbl Augenheilkd. 2012 Jan;229(1):21-7. Review. German.

PMID:
22338704
41.

Intravitreal bevacizumab for retinopathy of prematurity.

Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC.

J Ocul Pharmacol Ther. 2011 Dec;27(6):623-7. doi: 10.1089/jop.2011.0060. Epub 2011 Aug 8.

PMID:
21823985
42.

IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M.

Bilsborough J, Mudri S, Chadwick E, Harder B, Dillon SR.

J Immunol. 2010 Nov 15;185(10):6023-30. doi: 10.4049/jimmunol.0902769. Epub 2010 Oct 18.

43.

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.

Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA.

Arthritis Res Ther. 2010;12(2):R48. doi: 10.1186/ar2959. Epub 2010 Mar 19.

44.

Generation of a high-affinity Fcgamma receptor by Ig-domain swapping between human CD64A and CD16A.

Ellsworth JL, Hamacher N, Harder B, Maurer M, Bukowski TR, Lantry M, Noriega C, Rixon MW, Fox B, Lewis K, Meengs B, Rollins E, Greeff K, Meyer J, Birks C.

Protein Eng Des Sel. 2010 Apr;23(4):299-309. doi: 10.1093/protein/gzq007. Epub 2010 Feb 11.

PMID:
20150179
45.

Should you join a research study?

Harder B.

US News World Rep. 2009 Dec;146(11):68, 71. No abstract available.

PMID:
20027825
46.

Teaching excellence in nursing education: a caring framework.

Sawatzky JA, Enns CL, Ashcroft TJ, Davis PL, Harder BN.

J Prof Nurs. 2009 Sep-Oct;25(5):260-6. doi: 10.1016/j.profnurs.2009.01.017. Review.

PMID:
19751929
47.

Use of simulation in teaching and learning in health sciences: a systematic review.

Harder BN.

J Nurs Educ. 2010 Jan;49(1):23-8. doi: 10.3928/01484834-20090828-08. Epub 2010 Jan 4. Review.

PMID:
19731886
48.

Recombinant soluble human FcgammaR1A (CD64A) reduces inflammation in murine collagen-induced arthritis.

Ellsworth JL, Hamacher N, Harder B, Bannink K, Bukowski TR, Byrnes-Blake K, Underwood S, Oliver C, Waggie KS, Noriega C, Hebb L, Rixon MW, Lewis KE.

J Immunol. 2009 Jun 1;182(11):7272-9. doi: 10.4049/jimmunol.0803497.

49.

Lens capsular bag irrigation for low-grade endophthalmitis.

Schlichtenbrede FC, Spandau UH, Harder B, Jonas JB.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1273-6. doi: 10.1007/s00417-009-1085-7. Epub 2009 Apr 24.

PMID:
19390861
50.

Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration.

Jonas JB, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Libondi T, Spandau UH, Vossmerbaeumer U.

Ophthalmic Res. 2009;41(1):21-7. doi: 10.1159/000162113. Epub 2008 Oct 13.

PMID:
18849638

Supplemental Content

Loading ...
Support Center